Abstract
Aim of the study
In multiple-day chemotherapy (MDC), the combination of a 5-HT3-antagonist plus dexamethasone is still a standard of care. The role of a NK-1-antagonist
remains to be defined.
Patients and methods
Seventy eight cancer patients undergoing multiple-day chemotherapy of high (HEC) or
moderate (MEC) emetic risk received granisetron, dexamethasone plus aprepitant during
chemotherapy. After the end of chemotherapy, aprepitant plus dexamethasone was given
for another 2 days. Primary end-point was complete response (CR) in the overall phase
(day 1 until 5 days after the end of chemotherapy).
Results
Thirty eight patients underwent HEC and 40 patients underwent MEC for a median of
3.5 days. CR was seen in 57.9% and 72.5% of patients receiving HEC and MEC, respectively.
The tolerability of the aprepitant regimen over 5–7 days was comparable with a 3-day
aprepitant regimen.
Conclusions
This is the first report in MDC with a NK-1-antagonist containing antiemetic regimen
showing a favourable safety profile with good antiemetic efficacy.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.J Clin Oncol. 2006; 24: 2932-2947
- Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference.Ann Oncol. 2006; 17: 20-28
- Comparative activity of antiemetic drugs.Crit Rev Oncol Hematol. 2007; 61: 162-175
- Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy.J Clin Oncol. 1993; 11: 2391-2395
- Ondansetron.Lancet. 1991; 338: 753-754
- Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.Support Care Cancer. 2007; 15: 1293-1300
- Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions.Support Care Cancer. 2000; 8: 131-133
- The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 study group.J Clin Oncol. 2003; 21: 4112-4119
- Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment.Ann Oncol. 2006; 17: 1000-1006
- Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy.Ann Oncol. 2007; 18: 808-809
Article info
Publication history
Published online: January 09, 2009
Accepted:
November 25,
2008
Received:
November 23,
2008
Identification
Copyright
© 2008 Elsevier Ltd. Published by Elsevier Inc. All rights reserved.
